[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou Virotech Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,63,87,109,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639343","phase-2-a-study-of-vrt106-in-combination-with-radiotherapy-in-adult-patients-with-diffuse-midline-glioma--diffuse-intrinsic-pontine-glioma-100639343",false,"NCT07589257","A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma \u002F Diffuse Intrinsic Pontine Glioma","A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma \u002F Including Diffuse Intrinsic Pontine Glioma","Inclusion Criteria:\n\n* Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures.\n* Male or female adults aged 18 to 75 years at the time of signing the ICF.\n* Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \\>50% of the pons volume, with diffuse brainstem enlargement.\n* Karnofsky Performance Status (KPS) score ≥ 60.\n* Expected survival time ≥ 3 months.\n\nExclusion Criteria:\n\n* Individuals with extracranial metastases.\n* Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination.\n* Active hemorrhage detected on cranial MRI scan prior to enrollment.\n* Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants).\n* Prior receipt of oncolytic virus therapy or other gene therapy agents.","ALL","18 Years","75 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To Evaluate the Preliminary Efficacy and Safety\u002FTolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG\u002FDIPG",[27,28],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma",[27,28],"RECRUITING","2026-05-13",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":21},"2026-05-07",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"Guangzhou Virotech Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":42},"100638843","phase-2-a-study-of-vrt106-combined-with-camrelizumab-and-apatinib-for-advanced-hcc-100638843","NCT07589244","A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC","A Multicenter, Open-label Phase II\u002FIII Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures.\n* Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender.\n* Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition).\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Have an anticipated life expectancy of ≥ 3 months.\n* Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities.\n\nExclusion Criteria:\n\n* Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies.\n* Receipt of other unapproved investigational drugs\u002Fdevices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status.\n* History of splenectomy.\n* Pregnant or breastfeeding women.",{"count":51,"type":21},66,[24,53],"PHASE3","This is an open-label phase II\u002FIII clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).",[56],"HCC",[56],{"date":33,"type":34},{"date":31,"type":21},{"date":61,"type":21},"2029-06-30",{"name":40,"class":41},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":85,"locationsCount":86},"100600155","phase-1-a-study-of-vrt106-for-injection-in-patients-with-recurrentprogressive-glioblastoma-100600155","NCT07093814","A Study of VRT106 for Injection in Patients With Recurrent\u002FProgressive Glioblastoma","A Phase I\u002FII Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent\u002FProgressive Glioblastoma","Inclusion Criteria:\n\n* Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.\n* Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.\n* Diagnosed with recurrent\u002Fprogressive glioblastoma.\n* Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.\n* An expected survival time of≥3 months.\n* Have sufficient organ function.\n* Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment).\n* Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.\n\nExclusion Criteria:\n\n* Patients with extracranial metastases.\n* Previously received treatment with oncolytic viruses, gene therapy.\n* Subject has received treatment with other unlisted clinical investigational drugs\u002Fdevices within 4 weeks prior to the first dose of VRT106.\n* Subject is known to have an allergic reaction to any of the components of VRT106.\n* Patients who can't have a cranial MRI scan.\n* Women who are breastfeeding.","70 Years",{"count":72,"type":21},42,[74,24],"PHASE1","This study is an open-label, single-arm Phase I\u002FII clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent\u002Fprogressive glioblastoma.",[77],"Glioblastoma",[77],"2025-12-29",{"date":81,"type":34},"2026-01-02",{"date":83,"type":34},"2025-09-02",{"date":61,"type":21},{"name":40,"class":41},11,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100544441","phase-1-a-study-of-recombinant-oncolytic-virus-m1vrt106-in-patients-with-solid-tumors-100544441","NCT06368921","A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.\n* Males and females at 18-75 years of age, inclusive, at the Screening Visit.\n* Subjects must have histological or cytological diagnosis of locally advanced or metastatic solid tumors who are intolerable or refractory to the standard therapy.\n* Have at least one injectable lesion.\n* An Eastern Cooperative Oncology Group (ECOG) score of 0-1.\n* An estimated survival time of ≥ 12 weeks.\n\nExclusion Criteria:\n\n* Subject has received any anti-tumor treatment 4 weeks before using the IMP.\n* Subject has received any prior oncolytic viruses or other gene therapies.\n* Subject has a history of primary or acquired immunodeficient states, leukemia, lymphoma, acquired immunodeficiency syndrome (AIDS) or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.\n* Subject has received immunomodulatory drugs, including but not limited to thymosin, IL-2, IFN, etc. within 14 days prior to first administration of IMP.",{"count":95,"type":21},30,[74],"To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced\u002Fmetastatic solid tumors.",[99],"Solid Tumor","2025-12-22",{"date":102,"type":34},"2025-12-30",{"date":104,"type":34},"2024-06-19",{"date":106,"type":21},"2026-12",{"name":40,"class":41},3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100579593","phase-1-a-study-of-intravenous-vrt106-for-locally-advanced-or-metastatic-solid-tumors-100579593","NCT06826313","A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors","An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced\u002FMetastatic Solid Tumors by Intravenous Administration","Inclusion Criteria:\n\n1. Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.\n2. Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female.\n3. Subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment.\n4. Subjects have at least one measurable lesion.\n5. ECOG score of 0 to 28 days prior to first dose of IMP.\n6. An expected survival time of ≥ 12 weeks.\n7. Have sufficient organ function.\n8. Female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug.\n9. Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.\n\nExclusion Criteria:\n\n1. Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP.\n2. Subject has previously received oncolytic virus or other gene drug therapy.\n3. Subject has received treatment with other unlisted clinical investigational drugs\u002Fdevices within 4 weeks prior to the first dose of IMP.\n4. Subject is known to have an allergic reaction to any of the components of IMP.\n5. Women who are breastfeeding.",{"count":117,"type":21},12,[74],"A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors",[121],"Solid Tumors",[99,123,124],"Oncolytic Virus","VRT106","2025-07-15",{"date":127,"type":34},"2025-07-18",{"date":129,"type":34},"2025-03-19",{"date":131,"type":21},"2027-03-01",{"name":40,"class":41},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":108},"100519683","phase-1-a-study-of-intravenous-m1-c6v1-for-locally-advanced-or-metastatic-solid-tumors-100519683","NCT06046742","A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors","A Phase I, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Effects of M1-c6v1 for Treatment of Patients with Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Subjects must have diagnosis of locally advanced or metastatic solid tumors who are intolerable or refractory to the standard therapy.\n2. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.\n3. Males and females at least 18 years of age, inclusive, at the Screening Visit.\n4. Have at least one measurable lesion.\n5. An Eastern Cooperative Oncology Group (ECOG) score of 0-1, 1 week before the first administration of IMP.\n6. An estimated survival time of ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Subject has a history of primary or acquired immunodeficient states, leukemia, lymphoma, acquired immunodeficiency syndrome (AIDS) or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.\n2. Subject has received any anti-tumor treatment 4 weeks before using the IMP, including chemotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy.\n3. Subject has received systemic glucocorticoids (prednisone \\>10 mg\u002Fday or equivalent doses of similar drugs) or other immunosuppressive agents within 14 days prior to first administration of IMP.\n4. Subject has received immunomodulatory drugs, including but not limited to thymosin, IL-2, IFN, etc. within 14 days prior to first administration of IMP.",{"count":117,"type":21},[74],"A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors",[99],[145,99,123,124],"M1-c6v1","2025-03-10",{"date":148,"type":34},"2025-03-13",{"date":150,"type":34},"2024-07-10",{"date":152,"type":21},"2026-12-20",{"name":40,"class":41},""]